ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0640

Covid-19 and Rheumatic and Musculoskeletal Disease Patients: Infection Rates, Attitudes and Medication Adherence

Kieran Murray1, Sean Quinn2, Matthew Turk2, Anna O'Rourke3, Eamonn Molloy1, Lorraine O'Neill4, Anne Mongey5, Ursula Fearon6 and Douglas Veale7, 1Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, 2Saint Vincent's University Hospital, Dublin 4, Ireland, 3Saint James' University Hospital, Dublin 6, Ireland, 4Saint Vincent's University Hospital, Dublin, Ireland, 5Saint Vincent's University Hospital, Co Dublin, Ireland, 6Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, 7EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland

Meeting: ACR Convergence 2020

Keywords: COVID-19

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Infection-related Rheumatic Disease Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Covid-19 has caused >400,000 deaths. The relationship between RMDs, immunosuppressive medications and Covid-19 is unclear. This study explores Covid-19 prevalence, DMARD adherence, information sources and attitudes to virtual clinics amongst RMD patients during the current pandemic.

Methods: An anonymous online survey to assess Covid-19 status,  RMD diagnoses, adherence and information sources was performed. The respondents’ primary information source was assessed for quality and readability using validated scoring systems. Binary logistic regression was used to calculate odds ratios for symptoms of Covid-19.

Results: Table 1 shows respondent characteristics (n=1,381). RA was the most common diagnosis. 47 (3.7%) respondents had symptoms of Covid-19 and 6 (0.5%) tested positive, consistent with the general Irish population. Odds ratios for Covid-19 symptoms were higher amongst those with a SpA and other RMDs and lower in those on immunosuppression, csDMARDs, multiple immunosuppressives and those compliant with health authority guidance (Tables 2 and 3). Adherence to RMD medications was high at 84.1%. The most common reason for non-adherence was concern of an increased risk of infection (58.8%). 57.1% report using health authority guidelines for information on medication use. Importantly, adherence rates were higher amongst those who cited guidelines (p< 0.001), and conversely lower in those with Covid-19 symptoms (p=0.004). Moreover, we found the health authority guidance good quality and highly readable.

68.9% were unsure about potential Covid-19 therapies. Hydroxychloroquine was the most commonly selected potential agent (10.6%).  Those with Covid-19 symptoms were more likely to think NSAIDs had a role in treating Covid-19 (20.9% versus 8.4%, p=0.010) amongst those with Covid-19 symptoms.

Finally, the use of virtual clinics was supported by 70.4% of respondents.

Conclusion: The rate of Covid-19 positivity in RMD patients was similar to the general population. Covid-19 symptoms were lower amongst respondents on immunosuppressive medication and those adherent to medication guidelines. Adherence rates were higher than previous studies. Interestingly, a higher proportion of respondents adherent with medications cited health authority guidelines. This study suggests provision of high quality, readable information may significantly influence behaviour with better awareness of social distancing and cocooning guidance and increase adherence and decrease the spread of Covid-19. Respondents were supportive of health authority advice and virtual clinics.

Table 1. Respondent characteristics

Table 2. Odds ratios of Covid-19 symptoms by demographics and disease

Table 3. Odds ratio of COVID-19 symptoms by medications and information source


Disclosure: K. Murray, None; S. Quinn, None; M. Turk, None; A. O'Rourke, None; E. Molloy, None; L. O'Neill, None; A. Mongey, None; U. Fearon, None; D. Veale, AbbVie, 2, Health Beacon, 1, Janssen, 2, 8, Pfizer, 2, 5, 8, Novartis, 2, 5, 8, UCB, 2, 5.

To cite this abstract in AMA style:

Murray K, Quinn S, Turk M, O'Rourke A, Molloy E, O'Neill L, Mongey A, Fearon U, Veale D. Covid-19 and Rheumatic and Musculoskeletal Disease Patients: Infection Rates, Attitudes and Medication Adherence [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/covid-19-and-rheumatic-and-musculoskeletal-disease-patients-infection-rates-attitudes-and-medication-adherence/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/covid-19-and-rheumatic-and-musculoskeletal-disease-patients-infection-rates-attitudes-and-medication-adherence/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology